<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031702</url>
  </required_header>
  <id_info>
    <org_study_id>0905/14122018</org_study_id>
    <nct_id>NCT05031702</nct_id>
  </id_info>
  <brief_title>Camelia Sinensis for Basal Metabolism and Body Composition</brief_title>
  <official_title>Effectiveness of the Assumption of a Supplement Based on the Extract From Camelia Leaf Sinensis on Basal Metabolism and Body Composition in Overweight Women or With Obesity in Postmenopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda di Servizi alla Persona di Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda di Servizi alla Persona di Pavia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Camellia Sinensis leaf extract contributes to increasing energy expenditure and calorie&#xD;
      consumption by increasing thermogenesis. The purpose of this study is to evaluate the&#xD;
      efficacy of Camellia Sinensis on basal metabolism and body composition in overweight women or&#xD;
      with obesity in postmenopause.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes on energy expenditure</measure>
    <time_frame>Changes from baseline energy expenditure at 4 and at 8 weeks</time_frame>
    <description>Basal metabolic rate (Kcal/day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes on energy expenditure</measure>
    <time_frame>Changes from baseline energy expenditure at 4 and at 8 weeks</time_frame>
    <description>24 h azoturia (g/24 h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on body composition</measure>
    <time_frame>Changes from baseline body composition at 4 and at 8 weeks</time_frame>
    <description>Fat Free Mass (g), Fat Mass (g), Visceral Adipose Tissue (g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometry</measure>
    <time_frame>Changes from baseline anthropometry at 4 and at 8 weeks</time_frame>
    <description>Weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometry</measure>
    <time_frame>Changes from baseline anthropometry at 4 and at 8 weeks</time_frame>
    <description>Body Mass Index (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometry</measure>
    <time_frame>Changes from baseline anthropometry at 4 and at 8 weeks</time_frame>
    <description>Waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on insulin resistance</measure>
    <time_frame>Changes from baseline insulin resistance at 4 and at 8 weeks</time_frame>
    <description>Homeostasis Model Assessment (pt) for evaluate insulin resistance if &gt; 2,4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on carbohydrate profile</measure>
    <time_frame>Changes from baseline carbohydrate profile at 4 and at 8 weeks</time_frame>
    <description>Glycemia (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on carbohydrate profile</measure>
    <time_frame>Changes from baseline carbohydrate profile at 4 and at 8 weeks</time_frame>
    <description>Insulin (mcIU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on lipid profile</measure>
    <time_frame>Changes from baseline lipid profile at 8 weeks</time_frame>
    <description>Total Cholesterol (mg/dl), High Density Lipoprotein Cholesterol (mg/dl), Low Density Lipoprotein Cholesterol (mg/dl), Tryglicerides (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on inflammation</measure>
    <time_frame>Changes from baseline inflammation at 8 weeks</time_frame>
    <description>C-Reactive Protein (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 8 weeks</time_frame>
    <description>Alanine Aminotrasferase (IU/l), Aspartate Aminotrasferase (IU/I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 8 weeks</time_frame>
    <description>Gamma Glutamyl Trasferase (U/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on citokine profile</measure>
    <time_frame>Changes from baseline citokine profile at 4 and at 8 weeks</time_frame>
    <description>Adiponectin (microg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on citokine profile</measure>
    <time_frame>Changes from baseline citokine profile at 4 and at 8 weeks</time_frame>
    <description>Leptin (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on plasma catecholamine profile</measure>
    <time_frame>Changes from baseline plasma catecholamine profile at 4 and at 8 weeks</time_frame>
    <description>Adrenalin (ng/ml), Noradrenalin (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on satiety</measure>
    <time_frame>Changes of satiety through 8 weeks</time_frame>
    <description>Haber test (pt) for evaluation of satiety from 0 (no satiety) to 10 (a lot of satiety)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Postmenopausal Disorder</condition>
  <arm_group>
    <arm_group_label>Dietary supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extract from Camellia Sinensis leaf</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablets of the same size as the active component</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Camellia Sinensis leaf extract</intervention_name>
    <description>2 tablets per day of 150 mg (1 before lunch and 1 before dinner)</description>
    <arm_group_label>Dietary supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets per day of 150 mg (1 before lunch and 1 before dinner)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopause&#xD;
&#xD;
          -  Overweight or obesity class I-II (Body Mass Index 25-39,9 Kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Changes in heart rhythm&#xD;
&#xD;
          -  Intolerance or allergy to components&#xD;
&#xD;
          -  Obesity class III (Body Mass Index &gt; 40 Kg/m2)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mariangela Rondanelli</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariangela Rondanelli</last_name>
      <phone>0382381739</phone>
      <email>mariangela.rondanelli@unipv.it</email>
    </contact>
    <contact_backup>
      <last_name>Mariangela Rondanelli</last_name>
      <phone>+390382381739</phone>
      <phone_ext>Rondanelli</phone_ext>
      <email>mariangela.rondanelli@unipv.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

